GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and
Relvar/Breo Ellipta in patients with COPD
Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD
EMA CHMP issues positive opinion for Trelegy Ellipta.
GSK announces phase III results published in NEJM of mepolizumab in patients with eosinophilic COPD at risk of exacerbations
Regulatory filings planned for 2017
Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study.
Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794). Upon exercise of this option and transition of the programme, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the asset.